A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105). | Res Sq;2024 Apr 29. | MEDLINE

Conteúdo principal 1 Busca 2 Rodapé 3

+A A -A Alto contraste

BVS - MINISTÉRIO DA SAÚDE

Informação e Conhecimento para a Saúde

português

Localizar descritor de assunto Busca Avançada EVID@Easy

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).

Mezzanotte-Sharpe, Jessica; ONeill, Anne; Mayer, Ingrid A; Arteaga, Carlos L; Yang, Ximing J; Wagner, Lynne I; Cella, David; Meropol, Neal J; Alpaugh, R Katherine; Saphner, Thomas J; Swaney, Robert E; Hoelzer, Karen L; Gradishar, William J; Abramson, Vandana G; Sundaram, P Kothai; Jilani, Shamim Z; Perez, Edith A; Lin, Nancy U; Jahanzeb, Mohammad; Wolff, Antonio C; Sledge, George W; Reid, Sonya A.

Afiliação

Mezzanotte-Sharpe J; Vanderbilt University Medical Center.
ONeill A; Dana-Farber Cancer Institute.
Mayer IA; Vanderbilt University Medical Center.
Arteaga CL; The University of Texas Southwestern Medical Center.
Yang XJ; Northwestern University.
Wagner LI; Wake Forest University.
Cella D; Northwestern University.
Meropol NJ; Case Western Reserve University.
Alpaugh RK; Fox Chase Cancer Center.
Saphner TJ; Aurora Health Care.
Swaney RE; Denver Health Medical Center.
Hoelzer KL; Memorial Healthcare System.
Gradishar WJ; Northwestern University.
Abramson VG; Vanderbilt University Medical Center.
Sundaram PK; Columbus NCI Community Clinical Oncology Research Program.
Jilani SZ; Good Samaritan Hospital.
Perez EA; Mayo Clinic.
Lin NU; Dana-Farber Cancer Institute.
Jahanzeb M; University of Miami.
Wolff AC; Johns Hopkins University.
Sledge GW; Stanford Cancer Institute.
Reid SA; Vanderbilt University Medical Center.

Res Sq ; 2024 Apr 29.

Article em En | MEDLINE | ID: mdl-38746356

Palavras-chave

bevacizumab; breast cancer; chemotherapy; trastuzumab

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article